A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)
- Registration Number
- NCT01010906
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This was a 3-part study comparing the pharmacokinetics after administration of vaniprevir (MK-7009) for participants with mild, moderate or severe hepatic insufficiency with healthy matched control participants. The primary hypothesis is that the area under the curve (AUC) (0 to infinity) of vaniprevir for participants with mild, moderate, or severe hepatic insufficiency is similar to that observed in healthy matched controlled participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Hepatic Participants:
- Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
- Apart from hepatic insufficiency, is in good general health
- Has a diagnosis of chronic stable hepatic insufficiency
- Score on the Child-Pugh scale ranged from 5 to 6 (mild hepatic insufficiency); from 7 to 9 (moderate hepatic insufficiency); from 10 to 15 (severe hepatic insufficiency). Moderate and Severe participants must have had a 50% score of 2 or higher on at least one of the laboratory parameters (i.e., albumin, prothrombin time, bilirubin) at the prestudy visit.
Healthy Matched Participants:
- Females of reproductive potential test negative for pregnancy and agree to use an appropriate method of contraception during the study
- Is in good health
- Female is pregnant, lactating, expecting to become pregnant or donate eggs
- Has a history of stroke or seizures
- Has a history of cancer
- Is unable to refrain from the use of any prescription or non-prescription medication
- Consumes excessive amounts of alcohol or caffeinated beverages daily
- Has had surgery, donated blood or participated in another investigational study with in the last 4 weeks
- Is a regular user or past abuser of any illicit drug including alcohol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mild Hepatic Insufficiency (HI) Vaniprevir 300 mg Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir Healthy Control to Mild HI Vaniprevir 300 mg Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir Moderate HI Vaniprevir 300 mg Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir Healthy Control to Moderate HI Vaniprevir 300 mg Healthy, matched to moderate HI, control participants administered a single 300 mg oral tablet of vaniprevir Severe HI Vaniprevir 200 mg Participants with severe HI administered a single 200 mg oral tablet of vaniprevir Healthy Control to Severe HI Vaniprevir 200 mg Healthy, matched to severe HI, control participants administered a single 200 mg oral tablet of vaniprevir
- Primary Outcome Measures
Name Time Method Area Under the Curve (AUC) (0-infinity) of Vaniprevir in Blood Plasma Following Single Dose Administration 0-48 hours postdose Participants were administered a single dose of vaniprevir; then their blood was collected at the following time points: 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32 and 48 hours postdose. The AUC (0-infinity) of vaniprevir in blood plasma was based on an analysis of covariance (ANCOVA) model used to analyze natural log-transformed values that were back-transformed to derive geometric least-squares mean and confidence interval.
- Secondary Outcome Measures
Name Time Method Maximum Concentration (Cmax) of Vaniprevir in Blood Plasma Following Single Dose Administration 0-48 hours postdose Participants were administered a single dose of vaniprevir; then their blood was collected at the following time points: 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 32 and 48 hours postdose. The Cmax of vaniprevir in blood plasma was based on an ANCOVA model used to analyze natural log-transformed values that were back-transformed to derive geometric least-squares mean and confidence interval.